Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection, REDUCTOR: a prospective, single-arm, open-label phase II trial
- Blankenstein, S.A.
- Rohaan, M.W.
- Klop, W.M.C.
- Hiel, B. van der
- Wiel, B.A. van de
- Lahaye, M.J.
- Adriaansz, S.
- Sikorska, K.
- Tinteren, H. van
- Sari, A.
- Grijpink-Ongering, L.G.
- Houdt, W.J. van
- Wouters, M.W.J.M.
- Blank, C.U.
- Wilgenhof, S.
- Thienen, J.V. van
- Akkooi, A.C.J. van
- Haanen, J.B.A.G.
DOIAbstract
Objective: To evaluate the potency of short-term neoadjuvant cytoreductive therapy with dabrafenib plus trametinib (BRAF and MEK inhibitor) to allow for radical surgical resection in patients with unresectable locally advanced melanoma. Summary Background Data: Approximately 5% of stage III melanoma patients presents with unresectable locally advanced disease, making standard of care with resection followed by adjuvant systemic therapy impossible. Although neoadjuvant targeted therapy has shown promising results in resectable stage III melanoma, its potency to enable surgical resection in patients with primarily unresectable locally advanced stage III melanoma is still unclear. Methods: In this prospective, single-arm, phase II trial, patie...
Add to ORKG